Alpha Tau Medical Reports Increased Net Loss for 2025, Secures 2-Year Cash Runway, and Advances Alpha DaRT with Japan Approval

summarizeSummary

Alpha Tau Medical Ltd. filed its annual report for 2025, reporting a larger net loss but a strengthened cash position with a projected two-year runway, driven by successful equity raises and a recent marketing approval in Japan for its Alpha DaRT therapy.

check_boxKey Events

• Increased Net Loss for 2025

  The company reported a net loss of $42.6 million for the fiscal year ended December 31, 2025, an increase from $31.75 million in 2024, reflecting ongoing R&D investments.

• Strengthened Cash Position and Runway

  Cash and cash equivalents, short-term deposits, and restricted deposits increased to $76.9 million by year-end 2025, with management projecting at least a two-year operational runway.

• Successful Capital Raises in 2025

  Alpha Tau Medical raised approximately $45.5 million in net proceeds through two registered direct offerings of ordinary shares in April and December 2025.

• Alpha DaRT Receives Japan Marketing Approval

  In February 2026, the Alpha DaRT therapy received shonin pre-market approval from Japan's MHLW for unresectable locally advanced or recurrent head & neck cancer, a significant regulatory milestone.

auto_awesomeAnalysis

Alpha Tau Medical Ltd.'s annual report for 2025 highlights significant progress in its clinical development and commercialization efforts, despite an expected increase in net loss. The company successfully raised approximately $45.5 million through equity issuances in 2025, bolstering its cash reserves to $76.9 million and extending its operational runway for at least two years. A key milestone was the February 2026 shonin pre-market approval in Japan for its Alpha DaRT therapy for head and neck cancer, marking a crucial step towards commercialization. Additionally, the company reported positive interim clinical data across multiple cancer trials, including pancreatic cancer and HNSCC, and advanced its manufacturing capabilities with the completion of the first phase of its Hudson, NH facility. These developments indicate strong operational momentum and financial stability for a clinical-stage biotech.